Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific demethylase RSBN1L (RSBN1L) is an enzyme that catalyzes demethylation of methylated lysine residues within histone proteins, functioning in the epigenetic regulation of chromatin structure. Originally described as a testis-specific protein expressed in round spermatids, further studies indicate RSBN1L is expressed more broadly and is present in other germ cell stages. RSBN1L can demethylate both dimethyl and trimethyl lysine 20 on histone H4 (H4K20me2 and H4K20me3), converting them into monomethyl H4K20 (H4K20me1) and thereby influencing chromatin organization and gene expression during spermatogenesis. RSBN1L belongs to the RSBN1/Dpy-21/CEP530 family of demethylases[1][2]. At present, there are no documented drug interactions, disease associations, or direct clinical relevance for RSBN1L.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific demethylase RSBN1L (RSBN1L).